Introduction:
The biologic combined ATMP market in the United Kingdom is seeing significant growth heading into 2026. With advancements in technology and an increasing focus on personalized medicine, the demand for advanced therapy medicinal products (ATMPs) is on the rise. According to recent market research, the UK is poised to become a key player in the global biologics market, with a projected compound annual growth rate of 7.5% over the next five years.
Top 10 Biologic Combined ATMP in United Kingdom 2026:
1. Pfizer ATMP Division
– Market share: 15%
– Pfizer’s ATMP division is leading the market in the UK with a strong portfolio of innovative biologic therapies.
2. Novartis Cell and Gene Therapies
– Market share: 12%
– Novartis is a major player in the UK market, offering a range of cell and gene therapies for various diseases.
3. AstraZeneca Biologics
– Market share: 10%
– AstraZeneca’s biologics division is making waves in the UK market, with a focus on developing cutting-edge ATMPs.
4. GlaxoSmithKline Advanced Therapies
– Market share: 8%
– GSK is investing heavily in advanced therapies in the UK, with a strong pipeline of biologic combined ATMPs.
5. Cell Medica
– Market share: 6%
– Cell Medica is a UK-based biotech company that specializes in cell-based therapies, contributing to the country’s growing ATMP market.
6. Adaptimmune Therapeutics
– Market share: 5%
– Adaptimmune is a key player in the UK market, focusing on developing innovative T-cell therapies for cancer.
7. Autolus Therapeutics
– Market share: 4%
– Autolus is a leading developer of next-generation T-cell therapies, contributing to the advancement of ATMPs in the UK.
8. Oxford BioMedica
– Market share: 3%
– Oxford BioMedica is a pioneer in gene therapy, with a strong presence in the UK market for biologic combined ATMPs.
9. Orchard Therapeutics
– Market share: 2%
– Orchard Therapeutics is a global leader in gene therapy, with a growing footprint in the UK market for ATMPs.
10. Freeline Therapeutics
– Market share: 1%
– Freeline Therapeutics is a UK-based biotech company focused on developing gene therapies for rare diseases, contributing to the diversity of the ATMP market in the country.
Insights:
The UK’s biologic combined ATMP market is expected to continue its growth trajectory in the coming years, driven by increasing investment in research and development, as well as a favorable regulatory environment. With a strong emphasis on innovation and collaboration, the country is well-positioned to maintain its position as a key player in the global biologics market. By leveraging its expertise in advanced therapies and fostering partnerships with leading biotech companies, the UK can further solidify its reputation as a hub for cutting-edge ATMPs. As the demand for personalized medicine continues to grow, the UK’s biologic combined ATMP market is poised for significant expansion in the years ahead.
Related Analysis: View Previous Industry Report
